SCHEMBL4776154

SCHEMBL4776154

COC(=O)C(Br)c1ccc(C)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
ACHE P22303 1/20 0.38
ALOX5 P09917 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8881032 0.84 ESR1 (0.54) TDP1KMT2AALDH1A1LMNAESR1
SCHEMBL1564938 0.84 CYP1A2 (0.50) TDP1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL4013605 0.84 L3MBTL1 (0.46) L3MBTL1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL706814 0.82 HDAC3 (0.44) KMT2AALDH1A1LMNANPC1MAPT
SCHEMBL378101 0.82 KMT2A (0.49) KMT2AALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL473478 0.82 L3MBTL1 (0.49) L3MBTL1KMT2AALDH1A1
SCHEMBL6905840 0.82 MEN1 (0.46) KMT2AALDH1A1LMNASMN1; SMN2NPC1
SCHEMBL11564445 0.82 SLC6A3 (0.46) KMT2AALDH1A1ESR1ESR2
SCHEMBL31489313 0.82 HDAC3 (0.44) KMT2AALDH1A1LMNANPC1MAPT
SCHEMBL68152 0.82 KMT2A (0.64) KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282749-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-09-11 US disclosed
EP-4469445-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023173618-A1 CYCLIC GD (III) COMPLEX, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 国科温州研究院(温州生物材料与工程研究所) 2023-09-21 WO disclosed
WO-2023146991-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
US-9511052-B2 Mineralocorticoid receptor antagonists MERCK SHARP & DOHME CORP. (US) 2016-12-06 US disclosed
EP-2797910-B1 QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF CHIESI FARMA SPA (IT) 2015-09-16 EP disclosed
US-20150182503-A1 MINERALOCORTICOID RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2015-07-02 US disclosed
EP-2797910-A1 QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF Chiesi Farmaceutici S.p.A. (IT) 2014-11-05 EP disclosed
US-8748613-B2 Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof CHIESI FARMACEUTICI S.P.A. (IT) 2014-06-10 US disclosed
US-8748613-B2 Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof CHIESI FARMACEUTICI S.P.A. (IT) 2014-06-10 US disclosed
WO-2007014264-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS DOV PHARMACEUTICAL, INC. (US) 2007-02-01 WO disclosed
WO-2007014264-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS DOV PHARMACEUTICAL, INC. (US) 2007-02-01 WO disclosed
EP-0517812-A4 ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT MERCK & CO INC (US) 1995-10-18 EP disclosed
US-5449682-A Angiotensin II antagonists incorporating a substituted benzyl element MERCK & CO., INC. (US) 1995-09-12 US disclosed
US-5240938-A Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring MERCK & CO., INC. (US) 1993-08-31 US disclosed
EP-0517812-A1 ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT MERCK & CO. INC. (US) 1992-12-16 EP disclosed
WO-1991011999-A1 ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT MERCK & CO., INC. (US) 1991-08-22 WO disclosed
US-4231935-A ANXIOLYTICS AND ANALGESICS AMERICAN CYANAMID COMPANY (US) 1980-11-04 US disclosed
US-4196120-A 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS AMERICAN CYANAMID COMPANY (US) 1980-04-01 US disclosed
US-4131611-A ANXIOLYTIC, ANALGESIC AMERICAN CYANAMID COMPANY (US) 1978-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282749-A1 COMPOUNDS AND METHODS OF USE CYP1B1, CYP2C19, UGT1A1 L3MBTL1 4784/4885TDP1 2830/4885KMT2A 4270/4885
US-20150182503-A1 MINERALOCORTICOID RECEPTOR ANTAGONISTS NR3C2, MC2R, REN L3MBTL1 4841/4885TDP1 4781/4885KMT2A 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.